The overall prognosis of differentiated thyroid cancer is good， but a small number of patients will still develop local recurrence and distant metastasis， and lose iodine uptaking ability in the initial or treatment process， becoming radioactive iodine-refractory differentiated thyroid carcinoma （RAIR-DTC）， with a poor prognosis. Treatment options for RAIR-DTC patients are limited with poor results， and restoration of iodine uptaking capacity in RAIR-DTC through pharmacological promotion of redifferentiation is one of the important strategies for treatment.